[]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AES 2024
                          Not Confirmed
                          AES 2024
                          Not Confirmed

                          Details : The collaboration inked between the parties aims to develop oral medication through the discovery of small molecule inhibitors of Sclerostin.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 27, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Discovery

                          Sponsor : CSIR-CDRI

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank